Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Algeta Recruits Bayer To Deliver Prostate Cancer Drug Alpharadin To Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Big Pharma still hot for castration-resistant prostate cancer drugs, despite Phase III burns in the past.

You may also be interested in...



Algeta, Aspiring For Solo Success, Draws Bayer Bid After Xofigo Launch

The Norwegian biotech is keen to show it is not a one-trick pony, but its future might lie in the embrace of its big pharma partner Bayer.

Bayer Bids $2.4 Billion To Acquire Norwegian Biotech Partner Algeta

Bayer would gain full control of the potential blockbuster prostate cancer therapy, Xofigo, if successful.

Phase III Results For Bayer/Algeta's Alpharadin Hint Of Labeling Down The Line

In what's become a crowded field of drugs for advanced prostate cancer, Algeta takes aim at symptomatic bone metastases.

Related Content

Topics

UsernamePublicRestriction

Register

PS070050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel